RUO IVD Products: Why the Label Alone Does Not Set Intended Use
A research-use-only statement must be consistent with the manufacturer’s intended use. FDA’s RUO/IUO guidance looks beyond the presence of a label statement.
Review the complete product presentation
FDA’s final RUO/IUO distribution guidance addresses when an IVD product is appropriately labeled for research use only or investigational use only. A business should evaluate the intended use supported by its product presentation and distribution practices, rather than treating a disclaimer as a substitute for that assessment.
The guidance describes relevant evidence, including promotional claims and practices that support clinical diagnostic use. Read the original guidance for the specific circumstances. This article does not establish the classification or marketing pathway of an individual product.
A practical cross-functional review
- Compare the product label with the website and sales materials.
- Review the applications described in instructions, demonstrations, and technical support.
- Check whether different teams describe the same product differently.
- Identify how proposed new claims are reviewed before release.
- Record unresolved intended-use questions and route them to qualified regulatory personnel.
Do not turn an isolated fact into a conclusion
A customer’s identity or one phrase in a presentation may require context. Avoid an automatic conclusion that a product is compliant or noncompliant solely because of one selected fact. The purpose of the review is to assemble the relevant evidence and evaluate it against the applicable framework.
Likewise, research use only and investigational use only are not interchangeable labels. Use the FDA guidance and applicable regulations to determine which provisions fit the actual stage and intended use.
Keep the review current when the business changes
As a practical quality measure, reassess the position when a product, supported application, technical-support activity, or promotional message changes. Keep the assessment tied to the version actually being distributed.
This focused article concerns the RUO/IUO guidance. It does not rely on the 2024 laboratory-developed-test phaseout schedule as a current requirement or treat a laboratory’s separate obligations as interchangeable with those of a distributed IVD manufacturer.
Related inspection resources
Primary sources
Sources reviewed October 20, 2026. The preparation steps above are practical suggestions; the linked regulations and FDA documents define the applicable requirements.